Dennis Donohoe, M.D., Micell's Chief Medical Advisor, added, "We were very pleased with the two-year clinical findings in DESSOLVE I and II and specifically with respect to the unique finding of a lack of progression of late lumen loss over an 18 month period, in conjunction with excellent tissue healing as shown through detailed clinical imaging."
Data featured at TCT recently were included in a peer-reviewed paper published by JACC Cardiovascular Interventions: "First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus–Eluting Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)". Authors of this paper included co-principal investigators for the DESSOLVE I trial, William Wijns, M.D., Ph.D., of the Cardiovascular Center, Aalst, Belgium and John Ormiston, M.B.Ch.B., of the Mercy Angiography Unit, Auckland, New Zealand.
About the MiStent SES
The MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) is designed to optimize healing in patients with coronary artery disease. The rapidly absorbable coating of the MiStent SES is intended to precisely and consistently control drug elution and limit polymer exposure duration, thereby reducing the safety risks associated with current commercially available drug-eluting stent technologies.
The innovative MiStent SES system includes a proprietary stent coating t
|SOURCE Micell Technologies|
Copyright©2012 PR Newswire.
All rights reserved